{"filing":{"accession_number":"0001493152-26-025636","cik":"0001812360","ticker":"FOXOW","company_name":"FOXO TECHNOLOGIES INC.","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1812360/000149315226025636/form8-k.htm"},"events":[{"id":8540,"run_id":7497,"accession_number":"0001493152-26-025636","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"FOXO Technologies entered into a Strategic Technology License Agreement with founder Jon R. Sabes and LongevityFP Technologies that grants an exclusive, worldwide license to commercialize the Company's epigenetics IP portfolio (including two issued U.S. patents and proprietary datasets/algorithms) and includes a ten-year acquisition option allowing LongevityFP Technologies to acquire majority ownership of FLI under two alternative structures. This represents a material transaction involving the licensing and potential change of control of a significant asset (the epigenetics IP and FLI subsidiary), which would materially affect investor assessment of the Company's strategic direction and asset base.","company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXOW","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2460,"accession_number":"0001493152-26-025636","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"FOXO Technologies entered into a Strategic Technology License Agreement with founder Jon R. Sabes and LongevityFP Technologies that grants an exclusive, worldwide license to commercialize the Company's epigenetics IP portfolio (including two issued U.S. patents and proprietary datasets/algorithms) and includes a ten-year acquisition option allowing LongevityFP Technologies to acquire majority ownership of FLI under two alternative structures. This represents a material transaction involving the licensing and potential change of control of a significant asset (the epigenetics IP and FLI subsidiary), which would materially affect investor assessment of the Company's strategic direction and asset base.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:47:04.323748+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2460,"accession_number":"0001493152-26-025636","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"FOXO Technologies entered into a Strategic Technology License Agreement with founder Jon R. Sabes and LongevityFP Technologies that grants an exclusive, worldwide license to commercialize the Company's epigenetics IP portfolio (including two issued U.S. patents and proprietary datasets/algorithms) and includes a ten-year acquisition option allowing LongevityFP Technologies to acquire majority ownership of FLI under two alternative structures. This represents a material transaction involving the licensing and potential change of control of a significant asset (the epigenetics IP and FLI subsidiary), which would materially affect investor assessment of the Company's strategic direction and asset base.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:47:04.323748+00:00","company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXOW","filing_date":"2026-05-28"}]}